INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 131 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $15,000 | -99.2% | 11,524 | -99.1% | 0.00% | -100.0% |
| Q2 2017 | $1,958,000 | -53.6% | 1,246,959 | -4.6% | 0.04% | -53.1% |
| Q1 2017 | $4,221,000 | +133.9% | 1,306,679 | -2.3% | 0.08% | +125.0% |
| Q4 2016 | $1,805,000 | -15.0% | 1,336,821 | -1.8% | 0.04% | -16.3% |
| Q3 2016 | $2,123,000 | +9.1% | 1,360,822 | -7.0% | 0.04% | +2.4% |
| Q2 2016 | $1,946,000 | -74.9% | 1,463,042 | -0.5% | 0.04% | -74.7% |
| Q1 2016 | $7,753,000 | -32.1% | 1,471,111 | +1.2% | 0.17% | -30.5% |
| Q4 2015 | $11,414,000 | +0.4% | 1,453,981 | +8.0% | 0.24% | -5.2% |
| Q3 2015 | $11,373,000 | – | 1,345,930 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |